PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(6.38%)
USD 0.02
(6.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.27 Million CAD | 13.97% |
| 2022 | -1.48 Million CAD | 14.2% |
| 2021 | -1.72 Million CAD | 54.58% |
| 2020 | -3.8 Million CAD | -6.21% |
| 2019 | -3.57 Million CAD | 69.89% |
| 2018 | -11.88 Million CAD | -64.33% |
| 2017 | -7.23 Million CAD | -131.26% |
| 2016 | -3.12 Million CAD | -4907.47% |
| 2015 | -62.45 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -235.4 Thousand CAD | 44.36% |
| 2024 Q2 | -361.96 Thousand CAD | -53.76% |
| 2023 Q2 | -230.57 Thousand CAD | 39.51% |
| 2023 Q3 | -239.63 Thousand CAD | -3.93% |
| 2023 Q1 | -381.18 Thousand CAD | -214.17% |
| 2023 Q4 | -423.06 Thousand CAD | -76.55% |
| 2023 FY | -1.27 Million CAD | 13.97% |
| 2022 Q1 | -601.06 Thousand CAD | -28.11% |
| 2022 FY | -1.48 Million CAD | 14.2% |
| 2022 Q4 | 333.88 Thousand CAD | 141.86% |
| 2022 Q3 | -797.57 Thousand CAD | -91.44% |
| 2022 Q2 | -416.61 Thousand CAD | 30.69% |
| 2021 Q1 | -495.89 Thousand CAD | 69.82% |
| 2021 Q4 | -469.18 Thousand CAD | -21902.04% |
| 2021 Q3 | 2152.00 CAD | 100.28% |
| 2021 Q2 | -763.64 Thousand CAD | -53.99% |
| 2021 FY | -1.72 Million CAD | 54.58% |
| 2020 Q1 | -520.82 Thousand CAD | -581.61% |
| 2020 Q3 | 450.67 Thousand CAD | 121.58% |
| 2020 Q4 | -1.64 Million CAD | -464.54% |
| 2020 FY | -3.8 Million CAD | -6.21% |
| 2020 Q2 | -2.08 Million CAD | -300.92% |
| 2019 Q2 | -1.71 Million CAD | -45.5% |
| 2019 Q4 | -76.41 Thousand CAD | 87.49% |
| 2019 Q3 | -610.77 Thousand CAD | 64.36% |
| 2019 FY | -3.57 Million CAD | 69.89% |
| 2019 Q1 | -1.17 Million CAD | 79.4% |
| 2018 Q1 | -1.41 Million CAD | 47.41% |
| 2018 FY | -11.88 Million CAD | -64.33% |
| 2018 Q2 | -2.16 Million CAD | -52.82% |
| 2018 Q3 | -2.61 Million CAD | -20.72% |
| 2018 Q4 | -5.71 Million CAD | -118.69% |
| 2017 Q3 | -1.08 Million CAD | -23.7% |
| 2017 FY | -7.23 Million CAD | -131.26% |
| 2017 Q1 | -94.55 Thousand CAD | 20.86% |
| 2017 Q2 | -880.73 Thousand CAD | -831.44% |
| 2017 Q4 | -2.69 Million CAD | -147.34% |
| 2016 Q3 | -106.02 Thousand CAD | -297.5% |
| 2016 FY | -3.12 Million CAD | -4907.47% |
| 2016 Q1 | -32.29 Thousand CAD | -90.42% |
| 2016 Q4 | -119.47 Thousand CAD | -12.69% |
| 2016 Q2 | -26.67 Thousand CAD | 17.41% |
| 2015 FY | -62.45 Thousand CAD | 0.0% |
| 2015 Q3 | -1704.00 CAD | 0.0% |
| 2015 Q4 | -16.96 Thousand CAD | -895.36% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.3% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 80.62% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.396% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.406% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.957% |
| Mesoblast Limited | -87.95 Million USD | 98.551% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 29.994% |
| Genus plc | 7.9 Million USD | 116.133% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 88.299% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 65.65% |
| Marizyme, Inc. | -65.34 Million USD | 98.05% |
| ContraFect Corporation | -65.15 Million USD | 98.044% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 85.589% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 73.916% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 26.223% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 55.937% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 84.187% |
| MultiCell Technologies, Inc. | -380.07 USD | -335225.335% |
| Accustem Sciences Inc. | -3.74 Million USD | 65.982% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.534% |
| EV Biologics, Inc. | -1.26 Million USD | -0.579% |
| Q BioMed Inc. | -2.05 Million USD | 37.894% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 65.859% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -101.527% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 46.47% |
| Biomind Labs Inc. | -1.21 Million USD | -4.954% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 87.917% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 83.874% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.614% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 41.264% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -8410.089% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 81.749% |
| IMV Inc. | -36.48 Million USD | 96.507% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 91.97% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 78.092% |
| GB Sciences, Inc. | -1.36 Million USD | 6.404% |
| Alpha Cognition Inc. | -13.77 Million USD | 90.746% |
| HST Global, Inc. | -146.21 Thousand USD | -771.672% |
| CSL Limited | 2.64 Billion USD | 100.048% |
| Halberd Corporation | -79.67 Thousand USD | -1499.567% |
| Enzolytics Inc. | -2.17 Million USD | 41.453% |
| Resverlogix Corp. | -3.61 Million USD | 64.696% |
| Affymax, Inc. | -14.42 Million USD | 91.164% |
| SYBLEU INC | -180.3 Thousand USD | -606.846% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 59.814% |
| argenx SE | -295.05 Million USD | 99.568% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.964% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1400.481% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 67.922% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 57.885% |
| AVAX Technologies, Inc. | -6.41 Million USD | 80.129% |
| Zenith Capital Corp. | -10.59 Million USD | 87.972% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.665% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5383.482% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 69.26% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2008.634% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.866% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 58.911% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -20.682% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 34.617% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 66.628% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 36.439% |
| BioStem Technologies, Inc. | -8.48 Million USD | 84.976% |
| ONE Bio Corp. | 8.67 Million USD | 114.689% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -188.754% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 4.565% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 27.371% |
| Agentix Corp. | -1.37 Million USD | 7.258% |
| LadRx Corporation | 400.44 Thousand USD | 418.265% |
| Cell Source, Inc. | -5.32 Million USD | 76.049% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -206.747% |
| Regen BioPharma, Inc. | 1.02 Million USD | 224.52% |
| Regen BioPharma, Inc. | 1.02 Million USD | 224.52% |
| NovAccess Global Inc. | -4.76 Million USD | 73.277% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 118.405% |
| Itoco Inc. | -1.86 Million USD | 31.81% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 71.312% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 23.639% |
| Kadimastem Ltd | -3.3 Million USD | 61.466% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -366.153% |
| CytoDyn Inc. | -49.84 Million USD | 97.443% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1512.581% |
| Mobile Lads Corp. | -2.26 Million USD | 43.69% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -458.667% |
| Qrons Inc. | -789.34 Thousand USD | -61.459% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -35.362% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 38.953% |
| Rebus Holdings, Inc. | -1.02 Million USD | -24.948% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 20.975% |
| International Stem Cell Corporation | -131 Thousand USD | -872.879% |
| Bioxytran, Inc. | -4.28 Million USD | 70.223% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2248.303% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 49.631% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.349% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 39.713% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -63.208% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 59.77% |
| Neutra Corp. | -233.46 Thousand USD | -445.894% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.719% |
| PureTech Health plc | -65.69 Million USD | 98.06% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 94.007% |
| IXICO plc | -1.17 Million USD | -8.189% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 87.162% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.769% |
| CSL Limited | 2.64 Billion USD | 100.048% |
| Cellectis S.A. | -103.17 Million USD | 98.765% |